Shortening the infusion time of anticancer drugs: who will benefit?
作者信息
Margolin Kim, Gordon Michael
出版信息
J Clin Oncol. 2007 Jul 1;25(19):2642-3. doi: 10.1200/JCO.2007.10.7334.
PMID:17602068
Abstract
摘要
相似文献
1
Shortening the infusion time of anticancer drugs: who will benefit?
J Clin Oncol. 2007 Jul 1;25(19):2642-3. doi: 10.1200/JCO.2007.10.7334.
2
Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
J Clin Oncol. 2007 Aug 1;25(22):3382-3; author reply 3383. doi: 10.1200/JCO.2007.12.3760.
3
Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
Oncologist. 2010;15 Suppl 1:49-57. doi: 10.1634/theoncologist.2010-S1-49.
4
[Bevacizumab].
Rev Infirm. 2009 Jan-Feb(147):46-8.
5
[Monoclonal antibodies as adjuvant breast cancer therapy. Tumor cells in continuing sleep?].
MMW Fortschr Med. 2001 Nov 1;143(44):56.
6
Do oncologists believe new cancer drugs offer good value?
Oncologist. 2006 Feb;11(2):90-5. doi: 10.1634/theoncologist.11-2-90.
7
New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?
Oncologist. 2014 Dec;19(12):1291. doi: 10.1634/theoncologist.2014-0263.
8
[Antibody therapy in hematology and oncology - part 1].
Med Klin (Munich). 2008 Dec 15;103(12):843-59. doi: 10.1007/s00063-008-1133-9.
9
[Benefit-risk evaluation of new drugs as a basis for decisions on prioritization in hematology/oncology: methodical challenges and problem-solving strategies].
Onkologie. 2011;34 Suppl 1:6-10. doi: 10.1159/000323064. Epub 2011 Jan 17.
10
Acral dysesthesia and trastuzumab (Herceptin).
Australas J Dermatol. 2004 Aug;45(3):195-6. doi: 10.1111/j.1440-0960.2004.00091.x.
引用本文的文献
1
Cerebrovascular events after bevacizumab treatment: an early and severe complication.
Neurocrit Care. 2011 Dec;15(3):421-7. doi: 10.1007/s12028-011-9552-5.
Zotero 插件